SILEXION THERAPEUTICS CORP SLXN
ORD SHS NEW · Common Stock · CUSIP G1281K130
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q2 2025 | 2 |
| Q3 2025 | 4 |
| Q4 2025 | 6 |
| Q1 2026 | 7 |
| Q2 2026 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2025 | 3 | 2 |
| Q4 2025 | 3 | 0 |
| Q1 2026 | 2 | 2 |
| Q2 2026 | 0 | 7 |
Biggest buyers
| None |
Biggest sellers
| CITADEL ADVISORS LLC | Sold out | -20.9k |
| TWO SIGMA SECURITIES, LLC | Sold out | -11.7k |
| MONTAG A & ASSOCIATES INC | Sold out | -3.0k |
| UBS Group AG | Sold out | -517 |
| Pflug Koory, LLC | Sold out | -333 |
| JONES FINANCIAL COMPANIES LLLP | Sold out | -26 |
| SBI Securities Co., Ltd. | Sold out | -20 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
Moringa Sponsor, LP
13D · may seek influence
-7.3 pts · filed 2026-09-28
Stated purposeThe information contained in Item 3 is incorporated by reference in its entirety into this Item 4. On June 22, 2026, Moringa Sponsor, LP filed a claim against Silexion Therapeutics Corp and two of its senior officers (the "Claim"), alleging deliberate and systematic breaches of the Amended and Restated Promissory Note, dated August 15, 2024 (the "Note"). In the Claim, Moringa Sponsor, LP alleges, among other things, that Silexion breached the conditions governing conversion of indebtedness under the Note, including by failing to use the correct share price for conversions, failing to provide the required prior notice, effecting conversions below the minimum amount, and failing to deliver the shares within the required timeframe. Moringa Sponsor, LP seeks a declaration that the purported co… Full filing |
17.7% |
Fell to 5% or below in the last year: INTRACOASTAL CAPITAL, LLC (5.0%, 2026-08-18)
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q4 2024 | 0 | — | 0 | — | — |
| Q1 2025 | 0 | — | 0 | — | — |
| Q2 2025 | 0 | — | 0 | — | — |
| Q3 2025 | 0 | — | 0 | — | — |
| Q4 2025 | 0 | — | 0 | — | — |
| Q1 2026 | 0 | — | 1 | — | — |
| Q2 2026 | 0 | — | 0 | — | — |
| Q3 2026 | 0 | — | 0 | — | — |
None reported since 1 Apr 2026.
Holders, Q2 2026
| Manager | Shares | Change |
|---|